EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

From prediction to precision: how immunopeptidomics advances neoantigen discovery

Ilja E Shapiro, Michal Bassani-Sternberg

Trends in Cancer · 2026-06 · 12 (6) · 527-541

DOI: 10.1016/j.trecan.2026.02.003 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Trends in Cancer, 2026-06. Verfasst von Ilja E Shapiro und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), Lausanne, Vaud, Switzerland; Ludwig Institute for Canc…. Hauptthemen laut MEDLINE: Antigens, Neoplasm, Neoplasms, Peptides. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 134 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ludwig Institute for Cancer Research Ltd, Swiss Bridge Foundation, Cancer Research Foundation Switzerland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

T cell recognition of peptides presented by class I and II human leukocyte antigen (HLA) molecules is fundamental to cancer immunity and personalized immunotherapy. Neoantigens, peptides containing somatic mutations, are attractive therapeutic targets due to their tumor specificity and immunogenicity. Current neoantigen discovery pipelines rely on sequencing and computational predictions but often struggle to identify peptides that are both presented and immunogenic. Immunopeptidomics, which uses mass spectrometry to identify naturally presented HLA-bound peptides, enables detection of neoantigens displayed on tumor cells. This review explores how immunopeptidomics complements existing tools to refine neoantigen identification, improves machine learning prediction algorithms through immunopeptidomics-derived datasets, and distinguishes between mutant and wild-type immunopeptides. We also highlight emerging developments that will further integrate immunopeptidomics into personalized immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, NeoplasmNeoplasmsPeptidesHumansMass SpectrometryPrecision MedicineImmunotherapyImmunoinformaticsProteomicsMachine LearningAntigen PresentationMutationPrediction Algorithms

Stichwörter der Autor:innen

antigen discoveryantigen processingimmunopeptidomicsmass spectrometryneoantigenspersonalized immunotherapy

Substanzen

Antigens, NeoplasmPeptides

Autor:innen und Institutionen

  • Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), Lausanne, Vaud, Switzerland; Ludwig Institute for Cancer Research, Lausanne Branch, Lausanne, Vaud, Switzerland; Agora Cance…

Förderung

  • Ludwig Institute for Cancer Research Ltd
  • Swiss Bridge Foundation
  • Cancer Research Foundation Switzerland

Zitieren

APA

Shapiro, I. E., & Bassani-Sternberg, M. (2026). From prediction to precision: how immunopeptidomics advances neoantigen discovery. Trends in Cancer, 12(6), 527-541. https://doi.org/10.1016/j.trecan.2026.02.003

Vancouver

Shapiro IE, Bassani-Sternberg M. From prediction to precision: how immunopeptidomics advances neoantigen discovery. Trends in Cancer. 2026;12(6):527-541. doi:10.1016/j.trecan.2026.02.003

BibTeX
@article{Shapiro2026,
  author = {Shapiro, Ilja E and Bassani-Sternberg, Michal},
  title = {From prediction to precision: how immunopeptidomics advances neoantigen discovery},
  journal = {Trends in Cancer},
  year = {2026},
  volume = {12},
  number = {6},
  pages = {527--541},
  doi = {10.1016/j.trecan.2026.02.003}
}
Kostenlos starten →